Kisspeptin injection: Frequently asked questions

Expand your rotation pattern to 21 or 28 sites to maintain adequate recovery intervals between repeat uses. For twice-daily protocols, use morning sites from one anatomical zone (e.g., all abdominal sites in the morning) and evening sites from a different zone (e.g., all thigh sites in the evening). This prevents any single site from being used more than once per day. Increase minimum spacing to 1.5 inches to account for the higher injection frequency. Multiple-daily-dose protocols require more meticulous rotation documentation. A missed entry creates confusion that compounds quickly.

Stop using that site immediately and allow 4–6 weeks for tissue recovery. The lump is likely lipohypertrophy (localized fat accumulation) or a small hematoma from capillary damage during injection. Neither is dangerous, but both compromise peptide absorption at that location. Mark the affected site in your rotation log as temporarily excluded. If the lump persists beyond eight weeks or becomes painful, consult a medical professional. Persistent masses warrant evaluation to rule out abscess or other complications. In our experience working with peptide research protocols, 90% of injection site lumps resolve within six weeks when given complete rest.

Skip that site in your next rotation cycle to restore the recovery interval. Using the same site twice consecutively won't cause immediate harm, but it shortens tissue recovery time and increases lipohypertrophy risk if repeated. Adjust your rotation log: if you used Site 3 on both Day 3 and Day 4, use Site 4 on Day 5, continue the sequence, and skip Site 3 when you return to that zone (use Site 1, 2, skip 3, move to 4). This maintains the principle of adequate recovery time without restarting the entire rotation protocol.

Consult with a medical professional experienced in subcutaneous peptide administration to identify alternative anatomical sites suitable for your tissue distribution. Individuals with low body fat percentages (<12% in males, <20% in females) may have insufficient subcutaneous layers in standard zones. The flanks (sides of the torso between ribs and hips) and upper buttocks offer additional subcutaneous area for some individuals. Never attempt intramuscular injection of peptides designed for subcutaneous delivery. The altered pharmacokinetics invalidate research data and increase adverse reaction risk.

This suggests the peptide solution pH or osmolality may be irritating subcutaneous tissue, not a site-specific reaction. Kisspeptin reconstituted in bacteriostatic water typically has physiological pH (7.0–7.4) and should not cause significant discomfort beyond brief needle insertion sensation. If burning occurs at multiple sites across different anatomical zones, verify your reconstitution solution and storage conditions. Peptide degradation from temperature excursions or contamination can alter solution chemistry. For research protocols sourced from Real Peptides, our quality control ensures pH stability across the shelf life when stored correctly, but improper handling post-reconstitution can compromise this.